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Abstract
Purpose—Infused autologous tumor-infiltrating lymphocytes (TILs) and tumor-targeted 
chimeric antigen receptor (CAR)-T cells typically surround malignant lesions or penetrate small 
tumor nodules, but fail to penetrate large solid tumors, significantly compromising their antitumor 
impact. Strategies to overcome this primary challenge are largely required.
Experimental Design—We tested the effects of IL-12 plus doxorubicin on T cell penetration 
and efficacy in solid tumors in a murine lung cancer model, a murine breast carcinoma lung 
metastasis model and two human xenograft tumor models bearing large tumors (>10 mm).
Results—Intriguingly, this simple approach increased the numbers, the distribution, and the 
depth of penetration of infused CD8+ T cells in these tumors, including both TILs and CAR-T 
cells. This combined treatment halted tumor progression, and significantly extended survival time. 
Studies of the underlying mechanism revealed multiple effects. First, the combined treatment 
maintained the high ratios of immune-stimulatory receptors to immune-inhibitory receptors on 
infiltrated CD8+ T cells, reduced the accumulation of immune-suppressive regulatory T cells, and 
enhanced the numbers of T-bet+ effector T cells in the tumors. Second, doxorubicin induced 
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chemokines CXCL9 and CXCL10, which may attract NKG2D+CD8+ T cells to tumors, and this 
effect was boosted by IL-12–induced IFNγ accumulation in tumors, promoting the penetration of 
NKG2D+CD8+ T cells.
Conclusions—The deep penetration of infused T cells associated with combined IL-12 plus 
doxorubicin yielded striking therapeutic effects in murine and human xenograft solid tumors. This 
approach might broaden the application of T cell therapy to a wider range of solid tumors.
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INTRODUCTION
Many seminal studies have indicated that cytotoxic T cells inhibit the initiation and growth 
of malignant solid tumors (1,2). Tumor-infiltrating immune effector cells, particularly CD8+ 
T and natural killer cells, are associated with a promising prognosis and prolonged survival 
in both the early and late stages of malignancy (3,4). Sato et al. reported that colorectal 
cancer patients with a high density of infiltrated T cytotoxic and memory cells in their tumor 
had a much lower tumor recurrence rate and a prolonged survival time (5). The expression of 
co-stimulatory receptor CD28 on infiltrated T cells reduces the requirement for T cell 
receptor signaling during T cell activation and rescues exhausted CD8+ T cells (6,7). Tumor-
infiltrated NKG2D+CD8+ T cells recognize and eliminate tumor cells that exhibit NKG2D 
ligands (8,9). At the meanwhile regulatory T cells and immune checkpoint regulators (such 
as PD-1) in the tumor mass create an immune-suppressive environment that hampers the 
antitumor response from immune effector cells in advanced stages of cancer (10). Since the 
balance between immune activation (CD28 and NKG2D) and immune suppression (Tregs 
and PD1) may represent the effect of immune surveillance, the ratios of immune-stimulatory 
and immune-inhibitory signals in the tumor microenvironment are better predictors of 
immunotherapy outcomes (5,11).
The use of T cell immunotherapy has grown rapidly over the past decade; its success has 
spread from non-solid cancers to melanoma and, gradually, to other solid tumors. 
Nevertheless, majority of patients with advanced stage of cancers were associated with T 
cell exhaustion (12), and only a very limited number of patients with a solid tumor 
experience a response to T cell immunotherapy. These patients have been found to have 
strong intratumoral infiltration of T cells (13); high levels of cytotoxic T cell effector 
molecules, such as interferon gamma (IFNγ) (14); and high ratios of CD8/CD4 T cells in 
tumors (5). These parameters could serve as markers for evaluating the efficacy of T cell 
immunotherapy.
Infusion of autologous tumor-infiltrating lymphocytes (TILs) has been a remarkable 
breakthrough in the treatment of patients with refractory melanoma. In practice, however, 
the response rates are only about 50%, including a 10%-15% complete response rate (15–
17). Major challenges in TIL therapy include the reduced tumor-penetration ability of TILs 
after re-infusion and the immune suppressive tumor microenvironment. In recent clinical 
trials, patients were infused with 1.5–2×1011 TILs to ensure sufficient tumor-targeting TILs 
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and successful tumor remission (16,17). However, transferring such large numbers of TILs 
into cancer patients can cause off-target adverse effects. Approaches are needed that enable 
TILs to be delivered into large solid tumors more efficiently and therefore reduce the 
number of T cells that must be infused.
The loss of tumor-homing characteristics during ex vivo culture is one critical reason that 
TILs cannot reach tumor sites; thus, new therapies use T cells that have been engineered 
with receptors that recognize tumor antigens (such as CD19); this innovation is known as 
chimeric antigen receptor (CAR)-T cell therapy. CAR-T cell therapy has had substantial 
success in treating hematologic malignancies, but efficacy in treating large solid tumors is 
compromised. Because of their heterogeneity, solid tumor cells lack common antigens. 
Furthermore, host conditioning often prevents T cells from entering the tumor stroma. 
Caruana et al. made a fundamental breakthrough in CAR-T cell therapy by introducing the 
enzyme heparanase, which degrades the extracellular matrix to allow T cells to penetrate 
tumors (18). This discovery opens the door to use CAR-T cell therapy for solid tumors.
In our previous work, we found that the combination of systemic interleukin 12 (IL-12) 
expression plus low-dose doxorubicin facilitated accumulation of endogenous CD8+ T cells 
in solid tumors (up to 6mm in diameter) in mice in vivo (9). In this study, we hypothesized 
that IL-12 plus doxorubicin would also allow ex vivo expanded T cells, TILs, and CAR-T 
cells to penetrate large solid tumors. We found that this treatment not only boosted NKG2D
+CD8+T cell infiltration into large solid tumors but also synergistically upregulated the 
levels of the T cell–attracting chemokines CXCL9 and CXCL10 production, promoting 
accumulation of T cells to the tumor microenvironment and enhancing the effector functions 
of infiltrated T cells by increasing the ratios of stimulation to regulatory factors.
MATERIALS AND METHODS
Animal studies and cells
We purchased 6- to 8-week-old BALB/C, C57BL/6J and NSG mice from Jackson 
Laboratory (Bar Harbor, ME). The mouse care and handling procedures were approved by 
the Institutional Animal Care and Use Committee of The University of Texas MD Anderson 
Cancer Center (Houston, TX).
To create the transplant tumor mouse models, LLC tumor cells (1.5×105 per mouse) were 
subcutaneously inoculated into C57BL/6 and NSG mice. 4T1 tumor cells (1.5×105 per 
mouse) were orthotopically inoculated into BABL/C mice via the mammary fat pad. 4T1 
primary tumors were surgically removed on day 18 after inoculation. Lungs from mice in all 
treatment groups were intratracheally injected India ink (15% India Ink, 85% water, 3 drops 
NH4OH/100 ml), and then washed in Feket’s solution (300 ml 70% EtOH, 30 ml 37% 
formaldehyde, 5 ml glacial acetic acid) overnight. The tumor cell lines LLC and 4T1 were 
obtained from ATCC. Mel2549 (tumor-derived human melanoma) cells and autologous 
TILs, which were expanded and maintained in Dr. Chantale Bernatchez’s laboratory at MD 
Anderson Cancer Center (19), were inoculated subcutaneously (3×106 per mouse in 30 μL 
of phosphate-buffered saline solution [PBS]) into NSG mice. These mice also received an 
intravenous injection of autologous TILs (5×106) the day after each treatment. Nalm6 
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human lymphoblasts were mixed with Matrigel (1:1 in PBS) and inoculated subcutaneously 
(5×106 per mouse in 50 μL of solution). CD19–28ζ CAR-T cells were expanded and 
maintained in Dr. Gianpietro Dotti’s laboratory at University of North Carolina (18). Murine 
T cells were enriched from splenocytes using an EasySep kit and cultured in RPMI 1640 
medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. and 
treated with Mycoplasma Removal Agent from Bio-Rad to ensure mycoplasma negative 
before inoculation.
All the tumor cell lines were characterized by DNA fingerprinting within 6 months of 
initiating the experiments at MD Anderson Cancer Center’s Characterized Cell Line Core 
Facility, and treated with Mycoplasma Removal Agent from Bio-Rad to ensure mycoplasma 
negative before inoculation.
Tumor-bearing mice were treated with control DNA (10 μg/mouse), control DNA plus 
doxorubicin (1 mg/kg), mouse or human IL-12–encoding DNA (10 μg/mouse), or mouse or 
human IL-12–encoding DNA plus doxorubicin, followed by electroporation, as described 
previously (20). Tumor volume was calculated using the formula V = (π/8)×(a∗b2), where 
V = tumor volume in cubic centimeters, a = maximum tumor diameter, and b = diameter at 
90°.
Sham siRNA or CXCL9 and CXCL10 siRNA (500pmol) was injected intratumorally, 
followed by electroporation twice weekly. The electroporation was performed using the 




Plasmids and reagents—Our lab generated both mouse and human IL-12 constructs and 
confirmed by sequence analyses. DNA was prepared by using the endotoxin-free Mega 
preparation kit from Qiagen, Inc. (Valencia, CA) and following the manufacturer’s 
instructions. Doxorubicin (Bedford Laboratories, Bedford, OH) was purchased from the 
pharmacy at MD Anderson.
Immunohistochemical/immunofluorescence analysis—Frozen tumor sections were 
sequentially fixed with cold acetone, acetone plus chloroform (1:1), and acetone. Tissue 
sections were blocked with blocking buffer (5% normal horse serum and 1% normal goat 
serum in PBS) and then incubated with primary antibody overnight at 4°C, secondary 
antibody for 1 hour at room temperature. For immunohistochemical staining, the secondary 
antibody was biotin-conjugated and the sections were treated with ABC reagent and the 
nuclei counterstained with hematoxylin (Sigma-Aldrich, St. Louis, MO). Tumor sections 
were mounted with Cytoseal mounting medium (Life Technologies). For 
immunofluorescence staining, tumor sections were mounted in antifade with DAPI 
fluorescence mounting medium. Slides were visualized under a Nikon Eclipse Ti 
fluorescence microscope (Nikon, Melville, NY).
Hu et al. Page 4













Flow cytometry—A sample of each tumor from each treatment group was dissociated 
with liberase TM (Sigma-Aldrich, St. Louis, MO) enzyme cocktail. Cells were sequentially 
incubated with primary and secondary antibodies for 30 minutes each at 4°C. Stained cells 
were analyzed on an Attune acoustic focusing cytometer (Applied Biosystems, Foster City, 
CA). Flow cytometry data were analyzed by the FlowJo software program (BD Biosciences, 
San Jose, CA).
Antibodies—Alexa Fluor 488–conjugated anti-mouse CD45, anti-human CD45, violet 
421–conjugated anti-mouse CD4 and CD8, anti-human CD4 and CD8, and phycoerythrin-
conjugated anti-mouse or anti-human CD28, 41BB, NKG2D, CD39, PD-1, LAG3, TIM3, 
and FOXP3, as well as isotype control antibodies, were purchased from Biolegend (San 
Diego, CA). Rabbit anti-mouse and human CD3 and rabbit anti-human CD8 antibodies were 
purchased from Abcam (Cambridge, MA). Biotin anti-mouse NKG2D, mouse anti-human 
NKG2D, rabbit anti-human FOXP3 and anti-human Tbet antibodies were purchased from 
R&D Systems (Minneapolis, MN). Anti-mouse FOXP3 antibody was purchased from 
Thermo Fisher. Horseradish peroxidase–conjugated anti-rabbit IgG was purchased from Cell 
Signaling Technology (Danvers, MA).
Migration assay—Mel2549 and Nalm6 tumor cells (1×105) were treated with vehicle or 
doxorubicin (100 nM) in 600 μL of culture medium for 72 hours. The conditioned media 
were then collected and placed on the bottom chambers of a Boyden transwell chamber 
system. Human TILs or CAR-T cells (1×104) were labeled with violet tracker (Invitrogen, 
Carlsbad, CA), re-suspended in 100 μL of chemotaxis buffer (RPMI 1640/0.5% bovine 
serum albumin), and placed in the upper chambers with 5-μm pores (Corning, Corning, NY) 
for 1.5 hours at 37°C. Cells that migrated to the bottom chamber were collected, washed 
once with PBS, and counted by fluorescence-activated cell sorting.
ELISA—Tumor lysates were collected from tumor-bearing mice that underwent the 
indicated treatments at the indicated time points. The levels of IL-12 and IFNγ were 
measured by using ELISA Ready-SET-Go ELISA kits (eBioscience, San Diego, CA). The 
levels of human CXCL9 and CXCL10 in xenograft tumors were measured by using ELISA 
kits (LSBio, Seattle, WA).
RNA isolation and quantitative PCR—RNA was isolated from tumors with TRIzol 
reagent (Invitrogen). Residual genomic DNA was removed from total RNA using the 
TURBO DNA-free kit (Life Technologies).
Two micrograms of RNA were used for cDNA synthesis with the High-Capacity RNA-to-
cDNA kit (Life Technologies). The relative gene expression levels were determined by using 
the RT-qPCR and the SYBR Green labeling method in a StepOnePlus real-time PCR system 
(Life Technologies). The reaction contained 2 μL of cDNA, 12.5 μL of SYBR Green PCR 
Master Mix (Life Technologies), and 200 μM primer in a total volume of 25 μL. The PCR 
cycling conditions were as follows: 40 cycles of 15 s at 95°C and 60 s at 60°C. All samples 
were run in duplicate. The CT value of each sample was acquired, and the relative level of 
gene expression was calculated using the delta CT method, which was normalized to the 
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endogenous control, GAPDH. Data are expressed as n-fold relative to the control. The 
primer sequences for human genes were:
mCXCL9: F: AGCAGTGTGGAGTTCGAGGAA, R: 
GGTGCTGATGCAGGAGCAT
mCXCL10: F: GACGGTCCGCTGCAACTG, R: GGTGCTGATGCAGGAGCAT
mGAPDH: F: CCAGCCTCGTCCCGTAGAC, R: CGCCCAATACGGCCAAA
hCXCL9: F: AGGTCAGCCAAAAGAAAAAG, R: 
TGAAGTGGTCTCTTATGTAGTC
hCXCL10: F: AGCTCTACTGAGGTGCTATGT, R: 
GTACCCTTGGAAGATGGGAAAG
hGAPDH: F: ATGGAAATCCCATCACCATCTT, R: 
CATCGCCCCACTTGATTTTG
Statistical analysis—The directly measured outcomes were analyzed by using the two-
sided Student t-test to compare two treatment groups or one-way analysis of variance to 
compare more than two treatment groups. The statistical significance of each comparison 
was determined using GraphPad software (La Jolla, CA). A P value <0.05 indicated 
statistical significance. * equals P<0.05, ** equals P<0.01, *** equals P<0.005, **** equals 
P<0.001.
RESULTS
Adoptively transferred murine T cells accumulate in large solid tumors and lung metastatic 
nodules after treatment with IL-12 plus doxorubicin
Systemic immune therapy in mice has generally been effective only in small tumors (<5 mm 
in diameter) because the infused T cells do not penetrate into large tumors. Our previous 
discovery that treatment with a combination of IL-12 plus doxorubicin accumulated 
endogenous NKG2D+CD8+ T cells into small solid tumors (up to 6 mm in diameter) (9) 
prompted us to test whether this same treatment enriches exogenous NKG2D+ T cells in 
large solid tumors. We inoculated C57BL/6 and immune-deficient Nod-SCID-gamma 
(NSG) mice with Lewis lung carcinoma (LLC) murine lung cancer cells to establish solid 
tumors, and intentionally waited until the tumors reached 8–10 mm in diameter before 
beginning treatment with control DNA, mouse IL-12 plasmid DNA, doxorubicin, or mouse 
IL-12 plasmid DNA plus doxorubicin using a well-established method. This treatment was 
followed by adoptive intravenous transfer of exogenous T lymphocytes isolated from the 
tumor-bearing immune-competent C57BL/6 mice (21). The treatments were repeated one 
week later. Both IL-12 and doxorubicin were administered systematically to treat 
inaccessible tumors such as metastatic tumors. Tumors were collected 4 days after the 
second treatment to evaluate T lymphocyte penetration of tumors. Doxorubicin alone greatly 
increased the numbers of CD4+ T lymphocytes in periphery tumors compared to the control 
DNA treatment (Fig. 1A, Fig. S1A), whereas IL-12 plus doxorubicin allowed much greater 
penetration of CD8+ T lymphocytes into tumors (Fig. 1B).
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These results were supported by immunofluorescence staining of tumor sections with CD8 
(T cell marker) and NKG2D (activating receptor) showing that large numbers of NKG2D
+CD8+ T cells were localized in tumors after treatment with IL-12 plus doxorubicin, 
whereas only a few NKG2D−CD8+ T cells were found in tumors of mice in the control 
groups treated with doxorubicin, IL-12 DNA alone, or control DNA (Fig. 1C). Most of the 
CD8+ T cells recruited into tumors by IL-12 plus doxorubicin treatment were NKG2D
+CD8+ T cells (Fig. 1C). These results agree with the reported accumulation of endogenous 
NGK2D+CD8+ T cells in solid tumors induced by IL-12 plus doxorubicin, suggesting that 
this treatment also promoted infiltration of the exogenous murine NKG2D+CD8+ T 
lymphocyte subpopulation in solid tumors.
Next we sought to assess whether our systemic therapeutic approach could delay the 
metastatic diseases, the primary cause of cancer death. Metastatic mouse breast carcinoma 
cells 4T1 were orthotopically inoculated into BALB/C mice, and the primary tumors were 
surgically removed on day 18 after inoculation to establish lung metastases. The tumor 
bearing mice were treated with the same four groups of treatments as the LLC mice, 
followed by infusion of T cells that were isolated from 4T1 tumor–bearing BALB/C mice. 
Treatment with IL-12 plus doxorubicin followed by T cell infusion not only inhibited the 
primary tumor progression, and significantly prolonged the survival time of 4T1 tumor–
bearing mice, with 2/6 long-term survivors (Fig. 1D). Also, this treatment dramatically 
reduced the numbers and sizes of lung metastases (Fig. 1E). Mice treated with IL-12 plus 
doxorubicin plus adoptive T cell transfer showed much smaller pulmonary tumor nodules 
(less than 100μm in diameter) than mice in other treatment groups (Fig. 1F). Intriguingly, a 
few NKG2D−CD8+ T cells accumulated in lung metastatic tumors after treatment with 
control DNA or control DNA plus doxorubicin, whereas small numbers of NKG2D+CD8+ T 
cells infiltrated into the periphery of lung nodules in mice treated with IL-12. Strikingly, 
IL-12 plus doxorubicin led to influx of NKG2D+CD8+ T cells throughout the tumor 
nodules, suggesting that this treatment facilitates effector T cell penetration into metastatic 
tumors (Fig. 1G).
IL-12 plus doxorubicin enhances infiltration of autologous TILs into large tumors in a 
human melanoma xenograft tumor model
Although infusion of TILs into melanoma patients can result in tumor remission, about 50% 
of patients experience little response to the treatment. The capacity of TILs to penetrate into 
a tumor is often correlated with the outcome of TIL transfer. To determine whether the 
systemic administration of IL-12 plus doxorubicin boosts the penetration of autologous 
human melanoma-specific TILs as it did in mouse tumors, xenograft tumors were initiated in 
NSG mice via injection of patient-derived Mel2549 melanoma cells; the tumor-bearing mice 
were then divided into the same four treatment groups: control DNA, control DNA plus 
doxorubicin, human IL-12 DNA, human IL-12 DNA plus doxorubicin. Ex vivo–expanded 
autologous TILs were transferred intravenously as adoptive therapy one day after each 
treatment. Because TILs often lose their tumor-homing ability after ex vivo expansion and 
stimulation, most studies infuse large number (1×107) of T cells, but we transferred only 
5×106 T cells with the assumption that fewer T cells would be required because of their 
increased penetration into the solid tumors after IL-12 plus doxorubicin treatment. We 
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detected CD4+ T cells in the periphery tumor areas after control groups (control DNA, 
control DNA plus doxorubicin and IL-12 DNA) of treatments (Fig. S1B), but rarely any 
CD4+ T cells in tumors after IL-12 plus doxorubicin treatment, suggesting that CD4+ T cells 
may not play a critical role in our treatments. While doxorubicin alone slightly increased the 
TIL infiltration into tumors, the absolute numbers of infiltrated CD8+ TILs did not differ 
significantly between the group treated with IL-12 DNA and that treated with control DNA. 
In contrast, IL-12 plus doxorubicin remarkably increased the accumulation of infused CD8+ 
TILs in the large melanoma tumors (Fig. 2A).
To validate the distribution of infused TILs in tumors, we examined tumor sections from the 
peritumor and intratumor areas. All control groups showed TIL accumulation only in the 
peritumoral areas. In contrast, IL-12 plus doxorubicin led to 6-fold increase of TIL 
infiltration into both peritumoral and intratumoral areas (Fig. 2B). Significantly, only 
treatment with IL-12 plus doxorubicin increased NKG2D+CD8+ TIL cell numbers in the 
melanoma tumors (Fig. 2C).
Since infused T cells penetrated and distributed into large solid tumors after IL-12 plus 
doxorubicin treatment, we sought to determine the antitumor efficacy of this combinational 
therapy. Among the four treatments, only IL-12 plus doxorubicin significantly hampered the 
progression of melanoma tumors (Fig. 2D). This inhibition of tumor progression also 
significantly prolonged survival; two of the five mice that received IL-12 plus doxorubicin 
had particularly long-term survival (Fig. 2E). In contrast, the control groups (control DNA, 
doxorubicin, or IL-12 DNA) experienced no substantial improvement in tumor volume or 
survival duration (Fig. 2D, 2E).
CAR-T cells are enriched in tumors after treatment with IL-12 plus doxorubicin
CD19 CAR-T cell therapy is known to be successful in the treatment of hematologic 
malignancies in which T cells target CD19 antigen on malignant B cells. However, CAR-T 
cell therapy has so far been largely ineffective in treating large solid tumors. To test the 
hypothesis that IL-12 plus doxorubicin can boost CAR-T cell penetration into large solid 
tumors, we inoculated large numbers of CD19+ Nalm6 cells (5×106) mixed with Matrigel 
subcutaneously into immune-deficient NSG mice to generate solid tumors. CD19 28ζ CAR-
T cells were delivered using the same treatment as Mel2549 tumor model and T cell transfer 
strategy used in the other models until solid CD19+ Nalm6 tumors reached 6–8 mm in 
diameter. The accumulation of CD4+ T cells in the periphery tumor areas were detected after 
control groups of treatments, and was substantially reduced in the tumors treated with IL-12 
plus doxorubicin (Fig. S1C). The accumulation of CD8+ T cells in large solid tumors was 
assessed via flow cytometry after two treatment administrations. IL-12 plus doxorubicin (but 
not the other treatments) resulted in infiltration of a large number of CD8+ T cells into the 
solid tumors (Fig. 3A).
To gain insight into the localization of infiltrated CD8+ CAR-T cells, we dissected the center 
area of each tumor (>10 mm in diameter) for whole slide scanning. Small numbers of CD8+ 
CAR-T cells accumulated in the peritumoral areas following all the control treatments. In 
striking contrast, large numbers (more than 20-fold increase) of CD8+ CAR-T cells 
accumulated in the central tumor areas of mice receiving systemic IL-12 plus doxorubicin 
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treatment (Fig. 3B). Dual staining by human CD8 and NKG2D on tumor sections (Fig. 3C) 
confirmed that IL-12 plus doxorubicin allowed significantly greater numbers of NKG2D
+CD8+ T cells to penetrate into the tumor centers than the other treatments. This dramatic 
elevation of intratumoral infiltration by NKG2D+CD8+ CAR-T cells after IL-12 plus 
doxorubicin treatment reduced tumor volume and tumor weight by more than 5-fold, 
reflecting significantly enhanced antitumor efficacy (Fig. 3D, 3E).
Inhibition of immunosuppressive factors to enhance the persistence of tumor-infiltrated T 
cells
The immunosuppressive tumor microenvironment contains a network of factors, including 
intrinsic inhibitory receptors and extrinsic regulatory immune cells, that may impede the 
effector functions of antitumor cytotoxic T cells. The expression levels of inhibitory 
receptors reflect the status of infused T cells and are often altered after infusion in response 
to cytokines and the tumor microenvironment. The patterns of co-stimulatory and co-
inhibitory receptors may characterize the persistence of infiltrated T cells. To test the T cell 
persistence in mouse LLC tumor model, we primed splenic T cells from LLC tumor-bearing 
immune-competent mice with plate-bound CD3/CD28 antibodies and IL-2 for 24 hours 
before infusion and assessed expression of the co-stimulatory receptor CD28 and the 
exhaustion marker LAG3 and the checkpoint regulator PD-1 (Fig. 4A). These T cells were 
then infused into LLC tumor-bearing NSG mice following two administrations of control or 
systemic IL-12 plus doxorubicin treatment. Only IL-12 plus doxorubicin treatment 
maintained the expression levels of co-stimulatory and co-inhibitory receptors in the 
infiltrated T cells (Fig. 4B). Along with lower numbers of infiltrated T cells, we observed 
significant reductions in CD28 expression and substantial upregulation of LAG3 and PD-1 
in the control groups, suggesting that the infused T cells became exhausted and lost their 
effector functions. Intriguingly, the number of infiltrated CD8+ T cells, but not CD4+ T cells, 
exhibited a strong positive correlation with the ratios of CD28 expression to LAG3 and PD-1 
expression (Fig. S2), showing that the infused CD8+ T cells with higher ratios of co-
stimulatory/co-inhibitory receptors (S/I) were associated with high persistence states in large 
solid tumors.
Given that the enrichment of regulatory T cells (Tregs) in tumors often compromises the 
efficacy of T cell adoptive transfer (21–23), we stained LLC tumor sections with forkhead 
box P3 (FOXP3) antibody to quantify Treg infiltration in tumors (Fig. 4C). Tumors from 
control groups (control DNA, control DNA plus doxorubicin, or IL-12 DNA alone) showed 
notable Treg infiltration in clusters. In contrast, treatment with IL-12 plus doxorubicin 
remarkably reduced the accumulation of Tregs in large solid tumors (Fig. 4C), suggesting 
that this treatment inhibited the infiltration of suppressive immune cells so as to create an 
environment “friendly” to effector immune cells.
These encouraging results led us to determine whether the same highly persistent CD8+ T 
cells accumulated in human xenograft large solid tumors treated with IL-12 plus 
doxorubicin. CAR expression on CD4+ T and CD8+ T cells was confirmed on CD19 28ζ 
CAR-T cells before infusion (Fig. 5A). The expression levels of co-stimulatory receptors 
CD28, 41BB, and NKG2D, as well as inhibitory receptors CD39, PD-1, LAG3, and TIM3, 
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were assessed on expanded CAR-T cells before and after infusions plus the indicated 
treatments (Fig. 5B, 5C). On the basis of the median fluorescence intensity of each receptor 
on T cells, we created two heatmaps; these maps showed that after control treatments, 
infiltrated T cells displayed extremely low levels of co-stimulatory receptors CD28 and 
NKG2D (Fig. 5B) but increased levels of co-inhibitory receptor LAG3 (Fig. 5C). In striking 
contrast, IL-12 plus doxorubicin induced sustained expression of CD28 and NKG2D, with 
some suppression of PD1 and LAG3, in the tumor-infiltrating CD8+ T cells (Fig. 5B, 5C). 
The levels of these immune cell index markers suggest that IL-12 plus doxorubicin treatment 
enhanced CD8+ T cell effector function and prevented exhaustion of the infiltrated CD8+ T 
cells. We further converted the two heatmaps to better assess the S/I ratios on CAR-T cells 
in vitro and in vivo (Fig. 5D), and found that the control treatments dramatically reduced the 
S/I ratios on tumor-infiltrated T cells in vivo, whereas IL-12 plus doxorubicin maintained the 
S/I ratios on tumor-infiltrated CD4+ and CD8+ T cells as high as that on CAR-T cells before 
infusion.
Because it is well accepted that the Tbox transcriptional factor TBX21 (T-bet) plays a very 
crucial role in T cell development and functions, serving as a marker for effector T cells, we 
stained tumor sections from indicated groups with anti-T-bet antibody. T-bet+ cells were 
almost absent in the tumors from the control groups but were present in significantly greater 
numbers in the tumors from mice treated with IL-12 plus doxorubicin (Fig. 5E). Just as in 
LLC tumors (Fig. 4C), the infiltration of Tregs in Nalm6 tumors was dramatically reduced 
by treatment with IL-12 plus doxorubicin (Fig. 5F).Thus, our findings reveal that treatment 
with IL-12 plus doxorubicin produced the most powerful cytotoxic pattern of infiltrated T 
cells.
Roles of doxorubicin plus IL-12 in promoting cytotoxic T cell infiltration
Recent reports indicate that a variety of chemotherapeutic agents stimulate tumor cells to 
release T cell attractants CXCL9, CXC10, and CCL5 (22,23). We therefore first tested 
whether doxorubicin (100nM) induces these chemokines in tumor cells in vitro. Quantitative 
PCR analysis showed a remarkable induction of CXCL9 and CXCL10 in LLC cells and 
Mel2549 treated with doxorubicin (Fig. S3, data not shown). Additionally, the human CAR-
T cells we infused into mice expressed high levels of CXCR3, the receptor for CXCL9 and 
CXCL10 (Fig. 6A).
In theory, the chemokine-producing tumor cells should be able to promote T cell migration. 
To test this hypothesis, conditioned medium from Mel2549 or Nalm6 tumor cells treated 
with doxorubicin was placed at the bottom of Boyden transwell chambers. Violet cell 
tracker–labeled human TILs or CAR-T cells were cultured in the upper chambers for 1.5 
hours. The numbers of T cells that migrated to the lower chambers containing doxorubicin-
condition medium were significantly higher (5-fold for Mel2549 and 3-fold for Nalm6) than 
those that migrated to the lower chambers containing vehicle control medium (Fig. 6B).
Nevertheless, in our study, treatment with low-dose (1mg/kg) systemic doxorubicin alone 
was unsuccessful in attracting significant numbers of T cells to large solid tumors (Fig. 1–3), 
which led us to hypothesize that although doxorubicin or IL-12 alone may induce the T cell–
attractant chemokines to some extent, only IL-12 plus doxorubicin makes tumor cells 
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produce adequate chemokines to massively attract effector T cells to large solid tumors. 
Although IL-12 DNA was delivered systemically through intramuscular injection, it induced 
IL-12 production in tumors (Fig. 6C), which stimulates tumor-infiltrated T cells to secrete 
the effector molecule IFNγ (Fig. 6D). Treatment with IL-12 plus doxorubicin greatly 
augmented the intensity of infiltrated T cells, which in turn dramatically increased the 
expression of IFNγ in tumors (Fig. 6D). IFNγ is a well-known stimulator of chemokines 
CXCL9, CXCL10, and CXCL11, resulting in the synergistic induction of chemokines after 
treatment with IL-12 plus doxorubicin. Moreover, IFNγ may initiate positive feedback to 
stimulate T cell activation. In line with these data, the expression profile of T cell–associated 
chemokines in mouse and human xenograft tumors after the indicated treatments 
demonstrated that the levels of CXCL9 and CXCL10 mRNA transcripts were increased in 
tumors that had been treated with doxorubicin or IL-12 DNA alone and that expression of 
these chemokines was further boosted in tumors from mice treated with both IL-12 and 
doxorubicin (Fig. S4). Consistent with induction at the mRNA level, ELISA results showed 
that the secretion of CXCL9 and CXCL10 in Mel2549 and Nalm6 tumors were substantial 
induced after treatment with IL-12 plus doxorubicin (Fig. 6E). Strikingly, depletion of these 
chemokines from tumors impaired the recruitment of CD8+ T cells into tumors from mice 
treated with both IL-12 plus doxorubicin (Fig. 6F-6G), suggesting that the mechanism 
regulating CXCL9 and CXCL10 upregulation accounts for the induction of exogenous 
CD8+ T cell accumulation in large solid tumors by IL-12 plus doxorubicin.
DISCUSSION
We previously reported that IL-12 plus doxorubicin promoted endogenous T cell infiltration 
into mouse tumors (9), and others found that IL-12 plus cyclophosphamide induced 
macrophage- and T cell–dependent tumor eradication only in mouse fibrosarcomas, not in 
mouse melanoma, lung, pancreatic, or colon cancers (24–27). None of these studies showed 
tumor regression in human tumor models, nor did in-depth characterizations of tumor-
infiltrated T cells after treatment. Significantly, our study showed that treatment with IL-12 
plus doxorubicin successfully enriched not only murine T cells, but also clinically relevant 
human T cells (TILs, and CAR-T cells) in large solid tumors, both in peritumoral areas (<3 
mm from tumor margin) and in the centers of tumors 10 mm in diameter. Furthermore, this 
same treatment yielded high ratios of co-stimulatory/co-inhibitory receptors in the tumors 
and decreased the numbers of Treg cells, creating a tumor microenvironment friendly to 
infiltrated CD8+ T cells. The infiltration of highly active NKG2D+CD8+ T cells was 
associated with tumor remission and significantly extended survival in murine and human 
xenograft tumor models with large tumors (Fig. 1–3).
Although the infiltration of tumors by T lymphocytes, especially CD8+ cytotoxic T cells and 
memory T cells, has been reported to be associated with positive outcomes in terms of low 
relapse rates and prolonged overall survival in patients with melanoma (28,29) or lung 
(30,31), ovarian (4,5), breast (32,33), or colorectal cancer (34,35), the localization of 
infiltrated CD8+ T cells, which is part of the “immunoscore,” is often neglected. In fact, the 
localization of infiltrated CD8+ T cells affects the outcomes of T cell therapy in many 
cancers. Pages et al. observed that the presence of infiltrated CD8+ T cells in both the 
centers and invasive margins of colorectal tumors served as a marker of a better outcome 
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(35). Sato et al. showed prolonged survival with CD8+ T cells localized in the intraepithelial
—instead of the tumor stroma—of ovarian tumors (5). In melanoma metastases, the 
presence of CD8+ T cells throughout the tumor was correlated with prolonged survival (36). 
A recent report compared the prognostic outcomes of metastatic melanoma patients with 
intratumoral versus peritumoral T cell infiltration into the primary tumors and found that the 
high ratio of intratumoral to peritumoral values was strongly correlated with longer survival 
duration after dendritic cell therapy (13). Therefore, we studied not only the numbers of 
infiltrated CD8+ T cells but also their distribution. Treatment with IL-12 or doxorubicin 
alone attracted CD8+ T cells to the margins of tumors. Only the combination of IL-12 plus 
doxorubicin recruited CD8+ T cells to accumulate in much deeper areas of the tumors, 
reaching the center of tumors as large as 10 mm in diameter. Such deep penetration of CD8+ 
T cells into tumors led to massive tumor cell destruction and delayed tumor progression.
Besides the localization of infused T cells, another key parameter of the immune contexture 
is the ratio of immune-stimulatory and immune-inhibitory markers, which reflects the 
functional orientation of infused T cells. T cell therapy can not only augment the infiltration 
of both cytotoxic and regulatory T cells but also trigger negative feedback, inducing T cell 
exhaustion. In particular, long-term ex vivo expansion may result in the loss of co-
stimulatory receptor CD28 on the CD8+ T cell population, a loss associated with chronic 
stimulation (37,38). In fact, high numbers of infiltrated T cells are often correlated with high 
levels of immune-suppressive markers (39,40), which restrains the outcomes of CD8+ T cell 
infiltration (41). Therefore, it is critical to maintain the effector functions of infiltrated T 
cells (42).
Our assessment of T cell markers showed elevated numbers of stimulatory CD28+ and 
NKG2D+ T cells in large solid tumors after treatment with IL-12 plus doxorubicin. CD28 
signaling may reinvigorate the antitumor effect of the infiltrated CD8+ T cells. The deep 
infiltration of NKG2D+CD8+ T cells, besides the tumor specific cytotoxicity, recognize 
NKG2D ligand expressing tumor cells to induce NKG2D-mediated killing (8,9). 
Significantly, this same combination treatment (IL-12 plus doxorubicin) is able to restore 
NKG2D ligand expression in tumors (8), suggesting that this combination therapy could 
promote engagement between NKG2D+CD8+ T cells and NKG2D ligands on tumor cells to 
cause tumor rejection. NKG2D co-stimulation also facilitates the formation and rescue of 
memory CD8+ T cells (43).
Control treatments upregulated exhaustion markers PD1 and LAG3 on infiltrated T cells and 
increased Treg infiltration, whereas IL-12 plus doxorubicin prevented the exhausted and 
suppressive T cells present in tumors. It has been reported that CD28 co-stimulation 
augmented CD8+ T cell proliferation in tumors in response to impairment of PD-1 signaling 
(7). In the present study, treatment with IL-12 plus doxorubicin not only maintained high 
levels of CD28 but also suppressed PD-1 expression. Thus, both deep tumor infiltration and 
cell proliferation may account for the accumulation of great numbers of CD8+ T cells in the 
large solid tumors. Recent studies indicated that inhibitory receptors suppress the expression 
of IFNγ by T cells and that these T cells fail to proliferate despite antigen stimulation 
(44,45). Our treatment with IL-12 resulted in a long duration of IFNγ expression in tumors, 
which overcame the suppressive effect induced by low levels of inhibitory receptors. As a 
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result, the exogenous source of IFNγ from IL-12 treatment shifted the balance to favor 
CD8+ T cell antitumor immunity.
Several studies have highlighted the role of chemotherapy in promoting an antitumor 
immune response. The most frequently proposed mechanism is that chemotherapy, including 
anthracyclines, causes immunogenic tumor cell death, and the dead cells provide tumor 
antigens to stimulate immune responses (46–48). Recent studies revealed that chemotherapy 
also upregulates the expression of chemokines that attract effector T cells to tumors (49). In 
particular, Ma et al. showed that intratumoral administration of high-dose (2mM) 
doxorubicin induced expression of T cell–attractant chemokines CXCL9, CXCL10, and 
CCL5 mRNA in mouse sarcoma tumors in vivo, and in turn recruited CD8+ T and γδ T cells 
to tumors (22). Hong et al. claimed that temozolomide and cisplatin boosted the production 
of T cell–attracting chemokines, such as CXCL9, CXCL10, CXCL11, and CCL5, in human 
xenograft tumors in vitro and in vivo (23). Unlike these previous studies, we administered 
low-dose doxorubicin (1mg/kg) systemically in our tumor models (20) and showed that such 
low dose of doxorubicin induced the chemokines CXCL9 and CXCL10 in tumors, which 
was more or less expected. Surprisingly, doxorubicin in combination with IL-12 
significantly boosted this chemokine induction, which became the key mechanism for T cell 
penetration.
In fact, IFNγ is produced by immune cells (T cells, NK cells, and etc.) upon IL-12 
stimulation in tumors. Since there are very few effector immune cells recruited to tumors 
after IL-12 DNA alone treatment (Fig. 1–3), despite of enhanced IL-12 protein accumulation 
in tumors (Fig. 6C), it failed to boost IFNγ, a potent inducer of T cell attracting chemokines 
(Fig. 6D)(21). In contrast, in our combination therapy, doxorubicin allowed effector T cells 
to penetrate into tumors where in response to accumulated IL-12 (Fig. 6C), IFNγ production 
was greatly upregulated (Fig. 6D). Subsequently, IFNγ synergized with doxorubicin to 
enhance chemokine production which in turn recruit more effector T cells to amplify the 
antitumor immune response.
The correlation between the levels of T cell attracting chemokine, the numbers of infiltrating 
T cells and antitumor efficacy indicated that only IL-12 plus doxorubicin treatment induced 
production of CXCL9 and CXCL10 at levels sufficient to recruit the great numbers of CD8+ 
T cells into large solid tumors needed to obstruct tumor development. However, the source 
of the chemokines was not limited to tumor cells, because a higher induction of CXCL9 and 
CXCL10 was observed in tumors from C57BL/6 mice after doxorubicin treatment (data not 
shown). In fact, T cell–attracting chemokines are also secreted by macrophages, endothelial 
cells, and other stromal cells (50), and it remains unclear how much other cell types 
contribute to this induction of chemokines.
Unlike previously published strategies in which T cells had to be engineered to gain a tumor-
homing ability, our approach modified the tumor microenvironment to favor T cell 
accumulation in large solid tumors. Nevertheless, doxorubicin alone was inadequate at 
inducing the persistent infiltration of effector T cells. However, doxorubicin plus IL-12 
promoted the production of IFNγ, which further boosted CXCL9 and CXCL10 expression 
and stimulated the activation of infiltrated effector NKG2D+CD8+ T cells. These findings 
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suggest that TIL and CAR-T cell therapy may be extended beyond hematological 
malignancies and melanoma to a broad range of advanced large solid tumors.
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High density of tumor-infiltrated effector T cells improves the prognosis and prolongs 
survival of patients with solid tumors. However, the efficacy of T cell immunotherapy in 
treating large solid tumors remains very limited due to the inadequate effector T cell 
penetration into large solid tumors. Our discovery of IL-12 DNA plus doxorubicin co-
administration prior to TILs or CAR-T cell infusion can promote deep NKG2D+ CD8+ T 
cell infiltration into large solid tumors in different human xenograft models. This 
treatment reduced regulatory T cells infiltration, and enhanced the powerful effector 
patterns of infiltrated T cells in the immune-suppressive tumor microenvironment. Such 
deep penetration of antitumor effector T cells resulted in massive tumor cell destruction 
and halted tumor progression. In light of our findings, the use of TILs and CAR-T cell 
therapy can be extended beyond hematological malignancies and melanoma to a broad 
range of solid tumors.
Hu et al. Page 18













Figure 1. IL-12 plus doxorubicin enhanced the infiltration of infused T cells into murine solid 
tumors
LLC tumor-bearing NSG mice were given one of four standard treatments (control DNA, 
control DNA plus doxorubicin, mouse IL-12 DNA, or mouse IL-12 DNA plus doxorubicin), 
followed by an infusion of splenic T cells (5 million cells/mouse) that had been isolated and 
enriched from tumor-bearing C57BL/6 mice and stimulated with immobilized CD3 and 
CD28 antibodies for 24 hours. This cycle of treatment followed by T cell infusion was 
repeated 1 week later. Tumors were collected 4 days after the last T cell infusion. (A, B) The 
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tumor cell suspension was stained with anti-mouse CD45, CD4, and CD8 antibodies and 
subjected to flow cytometry analyses of CD4+ T (A) and CD8+ T (B) cell infiltration. Bar 
graphs represent the numbers of the indicated infiltrated lymphocytes, per 105 total cells in 
tumors, as means ± SEM. (C) Intratumoral T cell infiltration was determined by 
immunofluorescence staining. Sections from the centers of the tumors were stained with 
anti-mouse CD8 and NKG2D antibodies. Bar graphs represent the percentage of tumor-
infiltrating NKG2D+ CD8+ T cells in five views per slide and three slides per tumor as 
means ± SEM. (D-G) 4T1 tumor bearing mice were treated with four standard treatments as 
LLC mice, followed by an infusion of stimulated splenic T cells (5 million cells/mouse) on 
days 7, 14 and 21 after tumor inoculation. Tumors were surgically removed 4 days after the 
second administration. (D) Primary tumor sizes and survival time were monitored. Black 
arrows represent the dates of control or IL-12 plus doxorubicin treatments, and red arrows 
represent the dates of TIL infusion. (E) Lungs were collected from mice in all treatment 
groups, and stained with India ink. Macroscopic lung metastatic nodules were observed and 
counted in all lungs. Bar graphs represent the numbers of metastatic nodules as means ± 
SEM. (F) H&E staining of lung sections from each treatment group. (G) Sections from 
lungs were stained with anti-mouse CD8 and NKG2D antibodies. Bar graphs represent the 
percentage of tumor-infiltrating NKG2D+CD8+ T cells in five views per slide and three 
slides per tumor as means ± SEM. All results are representative of three repeated 
experiments.
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Figure 2. IL-12 plus doxorubicin enhanced the infiltration of infused autologous TILs into 
human melanoma xenograft solid tumors and delayed tumor development
NSG mice were inoculated with Mel2549 tumor cells (3×106 per mouse) to establish a 
human melanoma xenograft model (N=5). When tumors reached 3–5 mm in diameter, the 
tumor-bearing mice were subjected to one of four standard treatments: control DNA, control 
DNA plus doxorubicin, human IL-12 DNA, and human IL-12 DNA plus doxorubicin. After 
1 day, the mice received an infusion of 5 million autologous TILs. The mice received a 
second treatment and TIL infusion 7 days after the first administration. Tumors from each 
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treatment group were collected 4 days after the second T cell infusion. (A) A sample of each 
tumor was dissociated with liberase enzyme cocktail. Tumor cells in suspension were 
stained with anti-human CD45 and CD8 antibodies and subjected to flow cytometry analysis 
to quantify T cell infiltration into tumors. Bar graphs represent the numbers of tumor-
infiltrated CD8+ T cells per 105 total cells in tumors as means ± SEM. (B) Intratumoral T 
cell infiltration was determined by immunofluorescence staining. Sections from both the 
margins and centers of tumors were stained with anti-human CD8 antibody. Bar graphs 
represent the numbers of tumor-infiltrating T cells in five views per slide and three slides per 
tumor as means ± SEM. (C) Sections from the centers of the tumors were stained with anti-
human CD8 and NKG2D antibodies. Bar graphs represent the percentage of tumor-
infiltrating NKG2D+ CD8+ T cells in five views per slide and three slides per tumor as 
means ± SEM. (D) Tumor size was measured twice weekly beginning 5 days after 
inoculation. Black arrows represent the dates of control or IL-12 plus doxorubicin 
treatments, and red arrows represent the dates of TIL infusion. (E) Survival time was 
monitored and recorded. All results are representative of three repeated experiments.
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Figure 3. IL-12 plus doxorubicin enhanced the infiltration of infused CD19 CAR-T cells into 
human lymphoblast xenograft solid tumors with antitumor therapeutic effects
NSG mice were injected with Nalm6 tumor cells (5×106 cells/mouse) to establish a human 
lymphoblast xenograft model (N=5). When tumors reached 6–8 mm in diameter, the mice 
were subjected to one of four standard treatments, as shown in Figure 2. The next day, each 
mouse received 5 million CD19 28ζ CAR-T cells. The mice received a second treatment and 
CAR-T cell infusion 7 days after the first administration. (A) Tumors were collected from 
each treatment group 4 days after the second T cell infusion and a sample of each was 
dissociated with liberase enzyme cocktail. Suspended tumor cells were stained with anti-
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human CD45 and CD8 antibodies and subjected to flow cytometry analyses to quantify T 
cell infiltration into tumors. Bar graphs represent the numbers of tumor-infiltrated T cells per 
105 total cells in tumors as means ± SEM. (B) Intratumoral CD8+ T cell infiltration was 
determined by immunochemistry staining. Sections collected >10 mm from the tumor 
margin were stained with anti-human CD8 antibody. A representative section from each 
treatment group is shown, including nuclear counterstain on the left, DAB staining alone 
(red) on the right, and a random view of the core tumor area on the bottom. Bar graphs 
represent the percentage of tumor-infiltrating CD8+ T cells in five views per slide and three 
slides per tumor as means ± SEM. (C) Intratumoral T cell infiltration was determined by 
immunofluorescence staining. Tumor sections were stained with anti-human CD8 and 
NKG2D antibodies. Bar graphs represent the percentage of tumor-infiltrating NKG2D+ 
CD8+ T cells in five views per slide and three slides per tumor as means ± SEM. (D) Tumor 
size was measured twice weekly beginning 5 days after inoculation. Black and red arrows 
represent treatment dates. (E) Tumor weight was measured at the time of collection. All 
results are representative of three repeated experiments.
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Figure 4. IL-12 plus doxorubicin induced co-stimulatory receptor but suppressed co-inhibitory 
receptors on infused T cells in murine solid tumors
(A) Expression of co-stimulatory and co-inhibitory receptors on murine T cells were 
measured before infusion. Splenic T cells were isolated and enriched from LLC tumor-
bearing C57BL/6 mice, stimulated with immobilized CD3/CD28 antibodies for 24 hours, 
and stained with anti-mouse CD28, PD-1, and Lag3 antibodies for flow cytometry analyses. 
(B) Expression of co-stimulatory and co-inhibitory receptors on infused T cells in murine 
solid tumors. Cells dissociated from tumors from each treatment group were stained with the 
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indicated antibodies to detect CD28, PD-1, and Lag-3 expression on infiltrated T cells by 
flow cytometry. Shade histogram shows isotype control staining, and black line histogram 
shows the indicated antibody staining. Bar graphs represent percentages of the indicated cell 
populations as means ± SEM. (C) Treg infiltration was determined by 
immunohistochemistry staining. Tumor sections were stained with anti-mouse FOXP3 
antibody. Bar graphs represent the percentage of tumor-infiltrating Tregs in five views per 
slide and three slides per tumor as means ± SEM. All results are representative of three 
repeated experiments.
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Figure 5. IL-12 plus doxorubicin maintained high expression levels of CD28 and NKG2D on 
infused CD8+ CAR-T cells in human lymphoblast solid tumors
(A) Expression of CAR on CD4+ T and CD8+ T CD19 28ζ CAR-T cells. CAR-T cells were 
stained with anti-human CAR, CD4, and CD8 antibodies for flow cytometry analyses. (B, C, 
D) Heatmap based on the expression intensity of co-stimulatory (B), co-inhibitory (C) 
receptors, and the ratios of co-stimulatory to co-inhibitory receptors (D) on CAR-T cells 
before and after infusion. CAR-T cells before infusion or from cells dissociated from tumors 
after infusion were stained with the indicated antibodies, and CD28, 41BB, NKG2D, PD-1, 
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Lag-3, CD39, and TIM3 expression was detected on CD4+ and CD8+ T cells by flow 
cytometry. (B, C) The heatmap was created on the basis of mean fluorescence intensities. 
(D) The heatmap was based on the ratios of the co-stimulatory receptor positive to the co-
inhibitory receptor positive T cell numbers. (E) Tbet+ effector cell infiltration was 
determined by immunohistochemistry staining. Tumor sections were stained with anti-
human Tbet antibody. Bar graphs represent the percentage of tumor-infiltrating Tbet+ cells 
in five views per slide and three slides per tumor as means ± SEM. (F) Nalm6 tumor 
sections were stained with anti-human FOXP3 antibody, and HRP conjugated anti-mouse 
secondary antibody. Bar graphs represent the density of tumor-infiltrating Tregs in five 
views per slide and three slides per tumor as means ± SEM. All results are representative of 
three repeated experiments.
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Figure 6. Roles of doxorubicin and IL-12 in boosting the intratumoral infiltration of infused T 
cells
(A) Expression of CXCR3 on human CAR-T cells before infusion. Human CAR-T cells 
were subjected to CD3 and CXCR3 staining for flow cytometry analyses. (B) Migration 
assay of T cells and doxorubicin-treated tumor cells in Boyden transwell chambers. Tumor 
cells were pretreated with 100 nM doxorubicin or vehicle control for 72 hours, and one of 
the conditioned media was placed in the bottom chamber of each transwell. T cells were 
labeled with violet cell tracker and placed in the top chamber of each well, which had 5-μm 
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pores. Ninety minutes later, cells in the bottom chambers were counted via flow cytometry 
analyses. Bar graphs show the numbers of migrated T cells as means ± SEM. (C, D, E) 
Murine and human xenograft tumors from each treatment group were subjected to lysis in 
RIPA buffer. The tumor lysates were subjected to ELISA assay to detect IL-12 (C), IFNγ 
(D) as well as CXCL9 and CXCL10 levels (E). notx, no treatment; Dox (no T cells), 
doxorubicin treatment without T cell infusions. Bar graphs show the concentration of 
indicated proteins per milligram of total proteins in the tumor as means ± SEM. (F,G) LLC 
tumor-bearing mice (N=3) were treated with IL-12 plus doxorubicin as described in Fig. 1 
and were then subjected to intratumoral injection of control siRNA or CXCL9 siRNA plus 
CXCL10 siRNA followed by electroporation delivery twice a week. (F) Quantities of 
CXCL9 and CXCL10 mRNA (by PCR) in tumors. Bar graphs show the relative mRNA 
expression normalized to the control DNA-treated group as means ± SEM. (G) Flow 
cytometry of CD45+CD8+ cells in tumors. All results are representative of three repeated 
experiments.
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